News und Analysen

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites

Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated that the Personalis NeXT

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its Virtual Control Groups (VCG) initiative with Sanofi. The companies are working together to reduce animal

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today shared the results of a study published in the journal

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth

Agilent Technologies Inc., (NYSE: A) is introducing two new products at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics. The Agilent 7010D Triple Quadrupole GC/MS System which

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 45^th Annual

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 44^th Annual Growth Stock Conference on Tuesday, June 4^th, at 10:00 a.m. CT

Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Fields (TTFields) therapy in the treatment of

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib +

Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS^® (brentuximab vedotin) in combination with lenalidomide and rituximab for

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis’

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA^® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer frameworks. Based on decades of

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.57 billion for the second quarter ended April 30, 2024, a decline of 8.4% reported and 7.4% core⁽¹⁾ compared to the second quarter

Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024, at approximately 9:00 a.m. (ET) at

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological

DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William Blair 44th Annual Growth

Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000^® Index at the conclusion of Russell Investments’ annual reconstitution of its

Novocure (NASDAQ: NVCR) hat heute die ersten Wirksamkeits- und Sicherheitsdaten der TIGER-Studie veröffentlicht, die den Einsatz der Therapie mit Tumor Treating Fields (TTFields) in der klinischen

Novocure (NASDAQ: NVCR) today released topline efficacy and safety data from the TIGER study investigating the use of Tumor Treating Fields (TTFields) therapy in routine clinical care in the

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual